ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Category: Business
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England–(BUSINESS WIRE)–Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the trea…
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Breakthrough Gene Therapies Poised to Transform Cone Rod Dystrophy Treatment Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends – Forecast up to 2030” has been added to ResearchAndMarkets.com’s offering. As of 2024, the global cone rod dystrophy m…
OcuSciences Announces FDA Marketing Clearance of OcuMet Beacon in Retinal Health Assessment at ARVO
ANN ARBOR, Mich.–(BUSINESS WIRE)–OcuSciences, Inc., a leader in advanced ocular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its flagship device, the OcuMet Beacon, proprietary, non-invasive …
Glaukos Announces First Quarter 2025 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
Bausch + Lomb Announces First-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is pe…
Bausch + Lomb Announces First-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is pe…
Azalea Vision raccoglie 9 milioni di euro nella prima conclusione di un finanziamento di Serie A per promuovere lo sviluppo di una piattaforma di visione intelligente connessa
GHENT, Belgio–(BUSINESS WIRE)–Azalea (A-zuh-lay-ah) Vision, azienda di HealthTech (tecnologia sanitaria) che progetta il futuro della vista, oggi ha annunciato la prima conclusione del suo round di finanziamento di Serie A da 15 milioni di euro, racc…
Azalea Vision raccoglie 9 milioni di euro nella prima conclusione di un finanziamento di Serie A per promuovere lo sviluppo di una piattaforma di visione intelligente connessa
GHENT, Belgio–(BUSINESS WIRE)–Azalea (A-zuh-lay-ah) Vision, azienda di HealthTech (tecnologia sanitaria) che progetta il futuro della vista, oggi ha annunciato la prima conclusione del suo round di finanziamento di Serie A da 15 milioni di euro, racc…
アザレア・ビジョン、シリーズAラウンドの初回クロージングで900万ユーロを調達し、インテリジェントなコネクテッド・ビジョン・プラットフォームの開発をさらに推進
ベルギー・ゲント–(BUSINESS WIRE)–（ビジネスワイヤ） — 視覚の未来を作るヘルステック企業のアザレア・ビジョンは、1,500万ユーロのシリーズA資金調達ラウンドの初回クロージングで、900万ユーロを調達したことを発表しました。併せて、ロバート・J・デンプシーが取締役会会長に就任し、欧州および米国市場での戦略的成功を指揮することも発表しました。 アザレア・ビジョンのCEOであるエンリケ・ベガは次のように述べています。「今回のシリーズAのマイルストーンにおいてリピート投資家が積極的…
Azalea Vision完成A轮融资首次交割，募集900万欧元以进一步开发智能互联视觉平台
比利时根特–(BUSINESS WIRE)–(美国商业资讯)– 致力于开创视力未来的医疗科技公司Azalea (A-zuh-lay-ah) Vision今日宣布，其1500万欧元A轮融资已完成首次交割，成功募集900万欧元。同时，公司任命Robert J. Dempsey为董事会主席，以指导公司在欧洲和美国市场的战略发展。 Azalea Vision首席执行官Enrique Vega表示：“在这一A轮融资里程碑中，老投资者的踊跃参与再次证明了他们对我们的医疗器械以及为推动智能眼部健康未来所开展…
Azalea Vision lève 9 millions EUR dans le cadre de la clôture de la première phase d’un financement de série A pour poursuivre le développement de sa plateforme intelligente de vision connectée
GAND, Belgique–(BUSINESS WIRE)–Azalea (A-zuh-lay-ah) Vision, une société de heathtech qui conçoit l’avenir de la vue, vient d’annoncer aujourd’hui la clôture de la première phase de son cycle de financement de série A de 15 millions EUR, dans le cadr…
Azalea Vision recauda 9 millones de euros en el primer cierre de su ronda de Serie A para impulsar su plataforma de visión conectada inteligente
GHENT, Bélgica–(BUSINESS WIRE)–Azalea (A-zuh-lay-ah) Vision, empresa de tecnología sanitaria (HealthTech) que diseña el futuro de la visión, acaba de anunciar el primer cierre de su ronda de financiación de Serie A de 15 millones de euros, con la que…